Skip to main content

Table 2 Univariate logistic regression analysis for in-hospital mortality

From: Clinical benefits of inhaled ciclesonide for hospitalized patients with COVID-19 infection: a retrospective study

 

Odds ratio

95% confidence interval

p value

Inhaled ciclesonide

0.2676

0.1276–0.5612

0.0005

Age

1.0789

1.0455–1.1133

< 0.0001

Sex, male

1.0071

0.4899–2.0700

0.9847

Hypertension

3.2353

1.5251–6.8631

0.0022

Diabetes

2.4803

1.1914–5.1637

0.0152

Cardiovascular disease

2.5287

0.8556–7.4738

0.0934

Heart failure

32.2222

8.2954–125.1619

< 0.0001

Chronic obstructive pulmonary disease

1.4063

0.2947–6.7103

0.6689

Chronic kidney disease

11.1074

4.3914–28.0950

< 0.0001

Malignancy

1.6526

0.4457–6.1276

0.4524

Severe COVID-19 infection

2.3622

1.0572–5.2780

0.0361

High risk Shang’s CSS score

13.9931

4.7086–41.5847

< 0.0001

Systemic corticosteroids

4.6593

1.0810–20.0825

0.039

Remdesivir

1.6705

0.8112–3.4398

0.1638

Tocilizumab

4.5699

2.1703–9.6229

0.0001

Enoxaparin

1.5534

0.7436–3.2454

0.2413

Traditional Chinese medicine formula NRICM101

0.8287

0.3424–2.0056

0.6769

  1. COVID-19: coronavirus disease 2019; Shang’s CSS: Shang’s COVID-19 scoring system